跳转至内容
Merck

C-060

Supelco

Cyclobenzaprine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价

选择尺寸

1 ML
$55.10

$55.10


请联系客服了解存货情况

获取大包装报价

选择尺寸

变更视图
1 ML
$55.10

About This Item

经验公式(希尔记法):
C20H22ClN
CAS号:
分子量:
311.85
EC 号:
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24

$55.10


请联系客服了解存货情况

获取大包装报价

等级

certified reference material

质量水平

表单

liquid

特点

SNAP-N-SPIKE®, SNAP-N-SHOOT®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol (as free base)

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

SMILES字符串

Cl.CN(C)CC\C=C1\c2ccccc2C=Cc3ccccc13

InChI

1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H

InChI key

VXEAYBOGHINOKW-UHFFFAOYSA-N

基因信息

一般描述

Cyclobenzaprine is a muscle relaxant sold under the trade name Flexeril® to relieve skeletal muscle spasms and associated pain from acute musculoskeletal conditions. This Snap-N-Spike® Reference Solution is suitable for use in LC/MS or GC/MS methods for clinical toxicology, forensic analysis, or urine drug testing applications.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Flexeril is a registered trademark of ALZA Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 1

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Harvey Moldofsky et al.
The Journal of rheumatology, 38(12), 2653-2663 (2011-09-03)
To determine the effects of bedtime very low dose (VLD) cyclobenzaprine (CBP) on symptoms and sleep physiology of patients with fibromyalgia (FM), unrefreshing sleep, and the α-nonREM sleep electroencephalographic (EEG) anomaly at screening. Of 37 patients with FM in the
Yi Xiang et al.
Biomedical chromatography : BMC, 26(9), 1083-1088 (2011-11-29)
A sensitive, rapid and simple liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS/MS) method was developed for the quantitative determination of cyclobenzaprine in human plasma, to study the pharmacokinetic behavior of cyclobenzaprine capsule in healthy Chinese volunteers. With escitalopram as the internal
Lindsay T Morgan Bicknell et al.
International journal of psychiatry in medicine, 44(4), 305-314 (2012-01-01)
Lamotrigine is FDA-approved as a maintenance treatment of bipolar disorder, but its common off-label uses include bipolar depression and antidepressant augmentation in patients with major depressive disorder. Among other adverse effects, cutaneous reactions, particularly erythema multiforme, are cited as concerns
Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity?
P Ken Gillman
The American journal of emergency medicine, 27(4), 509-510 (2009-06-27)
Mona Darwish et al.
Clinical therapeutics, 33(6), 746-753 (2011-06-28)
The single-dose pharmacokinetic profile of cyclobenzaprine extended-release (CER) has been previously characterized and compared with the pharmacokinetics of cyclobenzaprine immediate-release (CIR) administered 3 times daily for 3 doses. The objective of this study was to characterize the multiple-dose pharmacokinetic properties

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持